Todd C. Davis - 22 Sep 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: By: /s/ Andrew Reardon For: Todd C. Davis
Issuer symbol: LGND
Transactions as of: 22 Sep 2023
Transactions value $: $237,529
Form type: 4
Filing time: 25 Sep 2023, 16:44:43 UTC
Previous filing: 13 Jun 2023
Next filing: 15 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Purchase	$238K	+4K	+5.79%	$59.38	73.1K	22 Sep 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $58.975 to $59.930. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $58.975 to $59.930. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.